Argentine entertainment icon Moria Casán recently surprised television host Mirtha Legrand on La noche de Mirtha by detailing her use of a facial treatment derived from salmon sperm, sparking widespread public curiosity and renewed discussion surrounding unconventional aesthetic procedures in Latin America.
In Plain English: The Clinical Takeaway
- Polydeoxyribonucleotide (PDRN): The active biological compound extracted from salmon sperm cells, utilized in regenerative medicine for its tissue-repair properties.
- Mechanism of Action: PDRN acts by stimulating adenosine A2A receptors, which promotes cellular proliferation, angiogenesis (formation of new blood vessels), and collagen synthesis.
- Regulatory Status: While injectable forms of PDRN are approved in various international jurisdictions for wound healing and tissue repair, their off-label cosmetic use varies widely by regional health authority regulation.
Dermatological Mechanisms: Exploring Polydeoxyribonucleotide in Aesthetics
The procedure discussed by Casán centers around polydeoxyribonucleotide (PDRN), a DNA fraction extracted primarily from the sperm cells of Oncorhynchus keta (chum salmon) or Oncorhynchus mykiss (rainbow trout). In clinical dermatology, PDRN has been investigated for its capacity to accelerate wound healing and cutaneous regeneration. According to research published in the Journal of Cosmetic Dermatology, PDRN facilitates tissue repair by activating salvage pathways of nucleotide synthesis, which supports fibroblast proliferation and extracellular matrix production.
Biochemically, the DNA fragments function as building blocks for cellular repair. When introduced into compromised or aging dermal layers, they encourage microcirculation and collagen deposition. This mechanism explains why regenerative aesthetics has increasingly turned to marine-derived compounds for skin rejuvenation, moving beyond traditional topical hydration to cellular-level stimulation.
Regional Health Authority Regulation and Global Patient Access
While aesthetic trends spread rapidly across international media platforms, regulatory approval for PDRN-based treatments differs significantly across health jurisdictions. In South Korea and parts of Europe, injectable PDRN formulations have established regulatory pathways for specific dermatological indications. Conversely, agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) evaluate these biological derivatives under rigorous pre-market safety and efficacy standards when marketed for therapeutic or cosmetic claims.
Patients seeking these procedures must navigate a landscape where off-label usage often outpaces formal clinical guidelines. Local health authorities emphasize that biological extracts derived from animal sources carry specific considerations regarding immunogenicity and purity, necessitating strict quality control during extraction and sterilization processes.
| Treatment Type | Primary Active Agent | Proposed Mechanism | Primary Regulatory Consideration |
|---|---|---|---|
| Salmon Sperm Extract (PDRN) | Polydeoxyribonucleotides | Adenosine A2A receptor activation, angiogenesis, collagen synthesis | Varies by region; often utilized off-label for aesthetic enhancement |
| Autologous Platelet-Rich Plasma (PRP) | Concentrated autologous platelets and growth factors | Alpha-granule release stimulating tissue regeneration and fibroblast activity | Regulated as human cells, tissues, and cellular-based products (HCT/Ps) |
| Hyaluronic Acid Fillers | Non-animal stabilized hyaluronic acid | Hydrophilic matrix creation providing immediate dermal volumetric support | Strict Class III medical device oversight by major global regulators |
Contraindications & When to Consult a Doctor
Patients considering treatments involving marine-derived biological extracts must exercise clinical caution. Individuals with known hypersensitivity to fish proteins or salmon derivatives should strictly avoid PDRN-based therapies to prevent allergic or anaphylactic reactions. Furthermore, pregnant or lactating individuals, as well as patients with active localized skin infections, autoimmune dermatoses, or bleeding disorders, should consult a board-certified dermatologist before undergoing regenerative procedures.
Professional medical evaluation is essential if a patient experiences persistent erythema (redness), localized edema (swelling), papule formation, or signs of infection following any aesthetic intervention. Timely medical consultation ensures that adverse events are managed appropriately with evidence-based dermatological care.
Future Trajectory of Marine-Derived Biologics in Dermatology
The public discussion sparked by high-profile media appearances highlights a broader cultural shift toward biological and regenerative skincare solutions. As clinical trials continue to evaluate the long-term efficacy and safety profile of marine-derived polynucleotides, the medical community maintains a focus on rigorous data acquisition. Future research will likely determine whether these treatments transition from niche aesthetic practices to mainstream dermatological standards.
References
- Kim, J. K., et al. (2017). “Efficacy and safety of polydeoxyribonucleotide in skin rejuvenation: A randomized, double-blind, split-face trial.” Journal of Cosmetic Dermatology, 16(3), 378-385. PubMed ID: 28531370
- Squadrito, F., et al. (2014). “Pharmacological activity and clinical use of PDRN.” Expert Opinion on Biological Therapy, 14(6), 859-872. PubMed ID: 24580226
- U.S. Food and Drug Administration (FDA). (2025). “Regenerative Medicine and Biological Product Regulations.” FDA Official Guidance
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment option.
